Therapix Biosciences IPO: How to Buy Therapix Biosciences Stock When It Goes Public

Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

Therapix Biosciences is expected to go public soon. Here's what we know about the IPO — and how to buy Therapix Biosciences stock when it's available.

What we know about the Therapix Biosciences IPO

Therapix Biosciences filed a registration form with the US Securities and Exchange Commission (SEC) to go public on the Nasdaq Capital Market as an American Depositary Share (ADS). This means that while the company is headquartered in Israel, you can easily buy shares using a US brokerage under the ticker symbol TRPX. Not yet an official IPO, this is one of the first steps of taking a private company public.

The exact IPO date has not been announced. Stocks are expected to open at a price of $6.00 per Unit. We'll update this page with more information as it becomes available.

How to buy Therapix Biosciences stock when it starts trading

Once Therapix Biosciences goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.

Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
Open your brokerage account. Complete an application with your details.
Confirm your payment details. Fund your account.
Research the stock. Find the stock by name or ticker symbol – TRPX – and research it before deciding if it's a good investment for you.
Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.

Finder's picks for buying Therapix Biosciences stock when it goes public

Go to site

$0 commission trading
Instant withdrawals with a 1.75% fee
Supports 250+ cryptocurrencies
High-yield account earns up to 4.65% APY

Disclaimer

Go to site

Trade options, futures, options on futures, stocks, ETFs
$0 commission to close options
Pro-grade platform and risk analysis tools

Go to site

Trade $0 commission stocks, ETFs, and options with as little as $1
After-hours trading available
Earn 4.5% interest on uninvested cash with Gold
24/7 customer support

How do similar companies perform?

It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. Looking at the performance of similar companies can help you decide if now is a good time to buy Therapix Biosciences stock.

See how the following stocks are performing, and view details like market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield.

Company summary
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.
Historical performance
Stock information
- Market capitalization: $40335970304
- P/E ratio: 59.234
- PEG ratio: 1.1706
- Dividend yield: 0%
Get more detailed information and learn how to buy ALXN.US stock
Company summary
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Historical performance
Stock information
- Market capitalization: $111865192448
- P/E ratio: 997.3333
- PEG ratio: 0.5217
- Dividend yield: 0.0343%
Get more detailed information and learn how to buy GILD.US stock
Company summary
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Historical performance
Stock information
- Market capitalization: $68756422656
- P/E ratio: 21.8831
- PEG ratio: 0.7213
- Dividend yield: 0.0464%
Get more detailed information and learn how to buy GSK.US stock
Company summary
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Historical performance
Stock information
- Market capitalization: $81813102592
- P/E ratio: 18.4145
- PEG ratio: 1.1079
- Dividend yield: N/A%
Get more detailed information and learn how to buy REGN.US stock

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

1 - 9 of 9

Name	Product USFST	Ratings	Available asset types	Stock trade fee	Minimum deposit	Cash sweep APY	Signup bonus
Tastytrade Finder Score: 4.4 / 5: ★★★★★ Tastytrade Finder Score: 4.4 / 5: ★★★★★		★★★★★	Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills	$0	$0	N/A	Get $50-$5,000	Competitive, capped options commissions, with a reliable trading platform designed for serious traders.	Go to site View details	loading Fetching your data...
Robinhood Finder Score: 4.5 / 5: ★★★★★ Robinhood Finder Score: 4.5 / 5: ★★★★★		★★★★★	Stocks, Options, ETFs, Cryptocurrency	$0	$0	4.5%	Get a free stock	Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.	Go to site View details	loading Fetching your data...
OPTO Finder Score: 3.1 / 5: ★★★★★ OPTO Finder Score: 3.1 / 5: ★★★★★		★★★★★	Stocks, ETFs	$0	$0	N/A	Earn up to $300	AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.	Go to site View details	loading Fetching your data...
EXCLUSIVE eToro Finder Score: 4 / 5: ★★★★★ eToro Finder Score: 4 / 5: ★★★★★	EXCLUSIVE	★★★★★	Stocks, Options, ETFs, Cryptocurrency	$0	$0	4.9%	FINDER EXCLUSIVE: Get a guaranteed $15 bonus and $10 in free crypto	No commission stock, ETF and options trades, with 4.9% interest on your options account balance and no options contract fees.	Go to site View details	loading Fetching your data...
Public.com Finder Score: 4.3 / 5: ★★★★★ Public.com Finder Score: 4.3 / 5: ★★★★★		★★★★★	Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account	$0	$0	4.35%	Get up to $10,000 and transfer fees covered	Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.	Go to site View details	loading Fetching your data...
Stash Finder Score: 3.7 / 5: ★★★★★ Stash Finder Score: 3.7 / 5: ★★★★★		★★★★★	Stocks, ETFs	$0	$0	0.1%	Get $10 when you sign up and deposit $5	Automated investing, individual stock and ETF investing and banking services for as low as $3 per month.	Go to site View details	loading Fetching your data...
Wealthfront Finder Score: 4.5 / 5: ★★★★★ Wealthfront Finder Score: 4.5 / 5: ★★★★★		★★★★★	Stocks, ETFs	$0	$500	5%	Get $50	Automated stock and bond ETF investing with the ability to trade individual stocks for as little as $1 apiece.	Go to site View details	loading Fetching your data...
Zacks Trade Finder Score: 3.8 / 5: ★★★★★ Zacks Trade Finder Score: 3.8 / 5: ★★★★★		★★★★★	Stocks, Bonds, Mutual funds, ETFs, CDs	$0.01	$250	2.83%	Get up to $500	Trade stocks, options, ETFs, mutual funds and bonds, with powerful trading tools and low margin rates.	Go to site View details	loading Fetching your data...
M1 Finance Finder Score: 4.1 / 5: ★★★★★ M1 Finance Finder Score: 4.1 / 5: ★★★★★		★★★★★	Stocks, ETFs, Cryptocurrency	$0	$100	4.25%	N/A	Build a custom portfolio of stocks and ETFs with automatic rebalancing. Plus, earn 4.25% APY with a high-yield cash account.	Go to site View details	loading Fetching your data...

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

More on investing

How to buy FAANG stocks

Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.

Read more…

How to buy soccer stocks

A simple guide to buying stocks in your favorite European soccer team.

Read more…

Inflation stocks

Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.

Read more…

Thank you for your feedback!

Written by

Dawn Daniels

Publisher

Dawn Daniels is a freelance content strategist and SEO manager and former editor at Finder, specializing in investments and lending. Dawn has edited more than 50 published books, including personal finance titles that have become best sellers on the Amazon Top 100. She holds a BA in English language and literature from Cornell College. See full bio

More resources on Finder

How to buy M/I Homes stock (MHO) How to buy Sancai Holding Group (SCIT) stock when it goes public

More guides on Finder

Best Paper Trading Apps to Practice Trading With Fake Money in 2024
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
5 Best International Stock Brokers to Invest in Foreign Assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
9 Best Discount Brokers of 2024 for Low-Cost Trading
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
9 Best Robo-Advisors for Automatic Investing
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Betterment alternatives
5 Betterment robo-advisor alternatives to consider when building your portfolio.
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
How to gift stock
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Acorns review 2024
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.

Ask a question

Click here to cancel reply.

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

How to buy Therapix Biosciences (TRPX) stock when it goes public

Here's everything we know so far about the Therapix Biosciences IPO.

What we know about the Therapix Biosciences IPO

How to buy Therapix Biosciences stock when it starts trading